JOP20190149A1 - استخدام مثبطات الكَيماز في معالجة الانتِباذ البِطانِي الرحمِي، التليف التال للجراحة والأمراض التي يميزها تكوّن التليف - Google Patents

استخدام مثبطات الكَيماز في معالجة الانتِباذ البِطانِي الرحمِي، التليف التال للجراحة والأمراض التي يميزها تكوّن التليف

Info

Publication number
JOP20190149A1
JOP20190149A1 JOP/2019/0149A JOP20190149A JOP20190149A1 JO P20190149 A1 JOP20190149 A1 JO P20190149A1 JO P20190149 A JOP20190149 A JO P20190149A JO P20190149 A1 JOP20190149 A1 JO P20190149A1
Authority
JO
Jordan
Prior art keywords
fibrosis
endometriosis
treatment
diseases
post
Prior art date
Application number
JOP/2019/0149A
Other languages
English (en)
Inventor
Zollner Thomas
Peters Michaele
Koch Markus
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of JOP20190149A1 publication Critical patent/JOP20190149A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الراهن باستخدام مشتقات اليوراسيل التي تحمل بدائل ثنائية الحلقة، بمفردها أو في توليفات مع مكونات فعالة أخرى في معالجة الأمراض، وتحديداً في معالجة الاضطرابات الالتهابية والتليفية، و/أو الوقاية منها، في معالجة الانتِباذ البِطانِي الرحمِي، التليف المصاحب للانتِباذ البِطانِي الرحمِي، ‎الُعضال الغُدي والألم المرافق لاضطراب الانتِباذ البِطانِي الرحمِي وكذلك التليف الصفاقي التالٍ للجراحة وتكوّن الالتصاقات.
JOP/2019/0149A 2016-12-20 2017-06-16 استخدام مثبطات الكَيماز في معالجة الانتِباذ البِطانِي الرحمِي، التليف التال للجراحة والأمراض التي يميزها تكوّن التليف JOP20190149A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16205339.1A EP3338780A1 (de) 2016-12-20 2016-12-20 Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind

Publications (1)

Publication Number Publication Date
JOP20190149A1 true JOP20190149A1 (ar) 2019-06-19

Family

ID=57570813

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0149A JOP20190149A1 (ar) 2016-12-20 2017-06-16 استخدام مثبطات الكَيماز في معالجة الانتِباذ البِطانِي الرحمِي، التليف التال للجراحة والأمراض التي يميزها تكوّن التليف

Country Status (19)

Country Link
US (1) US11266646B2 (ar)
EP (2) EP3338780A1 (ar)
JP (1) JP2020502272A (ar)
KR (1) KR20190098984A (ar)
CN (1) CN110072527A (ar)
AU (1) AU2017381324A1 (ar)
BR (1) BR112019012503A2 (ar)
CA (1) CA3047448A1 (ar)
CL (1) CL2019001713A1 (ar)
EA (1) EA201991292A1 (ar)
IL (1) IL266823B (ar)
JO (1) JOP20190149A1 (ar)
MA (1) MA47067A (ar)
MX (1) MX2019007377A (ar)
PH (1) PH12019501409A1 (ar)
SG (1) SG10202106586TA (ar)
TW (1) TWI753070B (ar)
UA (1) UA124848C2 (ar)
WO (1) WO2018114514A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2025182946A1 (ja) * 2024-02-27 2025-09-04 東レ株式会社 肥満細胞が病態を増悪させる疾患の治療及び／又は予防用医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1366461A (zh) * 2000-02-22 2002-08-28 三得利株式会社 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物
US7071220B2 (en) * 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US20040018984A1 (en) * 2002-07-17 2004-01-29 Mizuo Miyazaki Methods for preventing adhesion formation using protease inhibitors
CA2666658C (en) 2006-10-06 2015-01-20 Boehringer Ingelheim International Gmbh Chymase inhibitors
US9150556B2 (en) * 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
SG181883A1 (en) * 2009-12-25 2012-08-30 Daiichi Sankyo Co Ltd Seven-membered ring compound and pharmaceutical use therefor
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2929762A1 (en) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted 1,2,4-triazine-3,5-diones and the use thereof as chymase inhibitors
EP3066096A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile als chymase inhibitoren
CN105980381A (zh) 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
AP2016009181A0 (en) 2013-11-08 2016-04-30 Bayer Pharma AG Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid

Also Published As

Publication number Publication date
US11266646B2 (en) 2022-03-08
MX2019007377A (es) 2019-09-18
IL266823A (en) 2019-07-31
UA124848C2 (uk) 2021-12-01
SG10202106586TA (en) 2021-07-29
BR112019012503A2 (pt) 2020-04-14
MA47067A (fr) 2019-10-30
CA3047448A1 (en) 2018-06-28
EP3338780A1 (de) 2018-06-27
TWI753070B (zh) 2022-01-21
IL266823B (en) 2022-03-01
US20190381040A1 (en) 2019-12-19
TW201827053A (zh) 2018-08-01
WO2018114514A1 (de) 2018-06-28
EP3558316A1 (de) 2019-10-30
CN110072527A (zh) 2019-07-30
EA201991292A1 (ru) 2019-12-30
PH12019501409A1 (en) 2020-03-09
KR20190098984A (ko) 2019-08-23
JP2020502272A (ja) 2020-01-23
CL2019001713A1 (es) 2019-11-15
AU2017381324A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
NZ736665A (en) Heterocyclic amides as kinase inhibitors
WO2016029191A3 (en) Channel modulators
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
EP4272821A3 (en) Treatment of inflammatory diseases with inhibitors of c5a activity
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
NZ755605A (en) Compositions for modulating tau expression
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX2020006587A (es) Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
EP4335512A3 (en) Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
WO2016077639A3 (en) Nanovesicular therapies
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12019501409A1 (en) Use of chymase inhibitors for the treatment of endometriosis, post-operative fibrosis and diseases which are characterized by fibrosis formation
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
PH12016500525A1 (en) Substituted phenylalanine derivatives
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EP3220955A4 (en) Compositions for treating acute, post-operative, or chronic pain and methods of using the same